CRC-MTOs
Financiado
Colorectal Cancer Mouse Tumor Organoids as Pre clinical Models for Therapeutical...
Colorectal cancer (CRC) is one of the leading causes of death by cancer, which is largely associated to metastatic spread of the disease. Progress to develop efficient therapies, including immunotherapies, for patients with metast...
Colorectal cancer (CRC) is one of the leading causes of death by cancer, which is largely associated to metastatic spread of the disease. Progress to develop efficient therapies, including immunotherapies, for patients with metastatic CRC has been hampered by the lack of preclinical models to study late stage CRC in an immunocompetent background. We have developed the first genetic mouse model of advanced CRC in immunocompetent mice. This model is based in a biobank of mouse tumor organoids (MTOs) derived from tumors arising in compound mice bearing genetic alterations in 4 driver genes associated to CRC progression: WNT, EGFR, p53, and TGF-beta signaling. We have demonstrated that these MTOs represent an invaluable tool for basic and pre-clinical research in CRC, in particular to test immunotherapies (Tauriello et al., Nature 2018).
Despite its potential, the MTO biobank has limitations for translational research. They were generated as academic tools which has prevented their use in technology transfer projects and collaborations with pharmaceutical companies. In addition, they do not cover all the different CRC subtypes. We propose to create an improved and more complete second-generation MTO biobank that a) recreates the described pre-clinical model of advanced CRC, b) extends the model collection to other subsets of CRCs by means of genome editing tools and c) grants freedom to operate. These newly generated MTOs will represent unique tools ready to be licenced and exploited in strategic public-private collaborations with the final goal to aid in the development of new drugs to treat advanced CRC patients.
ver más
Duración del proyecto: 18 meses
Fecha Inicio: 2018-11-07
Fecha Fin: 2020-05-31
Fecha Fin: 2020-05-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-05-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2018-PoC:
ERC Proof of Concept Grant
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
FUNDACIO INSTITUT DE RECERCA BIOMEDICA IRB BA...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
23M
Perfil tecnológico
TRL
4-5
23M